The Malabsorption Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Malabsorption Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malabsorption Syndrome. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malabsorption Syndrome and features dormant and discontinued products.

GlobalData tracks six drugs in development for Malabsorption Syndrome by two companies/universities/institutes. The top development phase for Malabsorption Syndrome is discovery with three drugs in that stage. The Malabsorption Syndrome pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Malabsorption Syndrome pipeline products market are: Anagram Therapeutics and Elgan Pharma.

The key targets in the Malabsorption Syndrome pipeline products market include Insulin Receptor (IR or CD220 or INSR or EC, Amylase (EC 3.2.1.), and Lipase (EC 3.1.1.).

The key mechanisms of action in the Malabsorption Syndrome pipeline product include Insulin Receptor (IR or CD220 or INSR or EC Agonist with two drugs in Phase III. The Malabsorption Syndrome pipeline products include two routes of administration with the top ROA being Oral and four key molecule types in the Malabsorption Syndrome pipeline products market including Enzyme, and Recombinant Enzyme.

Malabsorption Syndrome overview

Malabsorption syndrome is a digestive disorder that prevents absorption of nutrients from the food through the small intestine, leading to indigestion and malnutrition. It can be caused by food allergies, food intolerances, infections, and digestive diseases. Some types of malabsorption include carbohydrate malabsorption, fat malabsorption, bile acid malabsorption, protein malabsorption, and vitamin, mineral, or trace element malabsorption. Treatments include lifestyle changes, a low-fat diet, total parenteral nutrition, and intake of fiber rich food.

For a complete picture of Malabsorption Syndrome’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.